PF chemotherapy combined with a PD-1/CTLA-4 bispecific antibody as first-line treatment in patients with recurrent/metastatic head and neck squamous cell carcinoma: a prospective, single-arm, phase II clinical study
This study evaluated the antitumor activity and safety of cadonilimab, a programmed cell death protein 1 (PD-1)/cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) bispecific antibody, combined with platinum/carboplatin and 5-fluorouracil (PF) chemotherapy as first-line treatment for patients with recurrent or met...